Ligand Pharmaceuticals (LGND)
(Delayed Data from NSDQ)
$80.06 USD
-1.28 (-1.57%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $80.25 +0.19 (0.24%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$80.06 USD
-1.28 (-1.57%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $80.25 +0.19 (0.24%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth B Momentum D VGM
Zacks News
Abbvie Inks Immuno-Oncology Deal with Harpoon Therapeutics
by Zacks Equity Research
AbbVie (ABBV) and Harpoon Therapeutics announced that they inked an immuno-oncology research collaboration to generate novel T-cell engagers for the treatment of cancer.
Novartis Reports Positive Results on Thrombocytopenia Drug
by Zacks Equity Research
Novartis AG (NVS) announced encouraging results on Revolade from the EXTEND study.
Impax Laboratories and Amneal Pharmaceuticals Agree to Merge
by Zacks Equity Research
Impax Laboratories (IPXL) and Amneal Pharmaceuticals announced an agreement to merge to form a new publicly traded company.
Zacks Industry Outlook Highlights: Novo, Vertex Pharmaceuticals, Celgene and Ligand Pharmaceuticals
by Zacks Equity Research
Zacks Industry Outlook Highlights: Novo, Vertex Pharmaceuticals, Celgene and Ligand Pharmaceuticals
Inovio Initiates Bladder Cancer Study With Roche's Tecentriq
by Zacks Equity Research
Inovio Pharmaceuticals (INO) will evaluate a combination of checkpoint inhibitor and T cell activator as a potential treatment for advanced bladder cancer in a new early stage study.
Shire's New Formulation of Oncaspar Gets CHMP Recommendation
by Zacks Equity Research
Shire's (SHPG) marketing authorization application for a new (dried) formulation of its leukemia drug, Oncaspar, received CHMP recommendation for approval in EU.
AcelRx's Opioid Painkiller Dsuvia Gets CRL, Shares Plunge
by Zacks Equity Research
AcelRx (ACRX) receives CRL for its opioid painkiller, Dusvia. The FDA has requested resubmission with additional safety data and recommended changes to drug administration.
Ligand (LGND) Signs Deal to Acquire Crystal Bioscience
by Zacks Equity Research
Ligand (LGND) inked a deal to acquire Crystal Bioscience, a leader in chicken-derived fully-human antibody generation, for $25 million in cash.
Amicus Therapeutics (FOLD) Soars: Stock Adds 9.2% in Session
by Zacks Equity Research
Amicus Therapeutics (FOLD) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Palatin Technologies (PTN) in Focus: Stock Moves 13.2% Higher
by Zacks Equity Research
Palatin Technologies (PTN) was a big mover last session, as the company saw its shares rise more than 13% on the day.
Catabasis Pharmaceuticals (CATB) Surges: Stock Moves 7.2% Higher
by Zacks Equity Research
Catabasis Pharmaceuticals (CATB) was a big mover last session, as the company saw its shares rise more than 7% on the day amid huge volumes.
MannKind (MNKD) in Focus: Stock Moves 7.8% Higher
by Zacks Equity Research
MannKind (MNKD) shares rose nearly 8% in the last trading session, amid huge volumes.
Ligand's Captisol Deals Set to Drive Growth in the Long Run
by Zacks Equity Research
Ligand's (LGND) Captisol formulation technology platform allows it to partner with several leading drug companies, thus helping it earn milestones and royalty payments in turn.
Ligand Pharma, Chipotle Mexican Grill, Arcelormittal, Ichor Holdings and Micron Technology highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Ligand Pharma, Chipotle Mexican Grill, Arcelormittal, Ichor Holdings and Micron Technology highlighted as Zacks Bull and Bear of the Day
Bull of the Day: Ligand Pharma (LGND)
by David Bartosiak
Drug stocks have become very hot lately and this off-the-radar name may soon be a big hit
Ascendis Pharma (ASND) Looks Good: Stock Adds 5.5% in Session
by Zacks Equity Research
Ascendis Pharma (ASND) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Aimmune Therapeutics (AIMT) in Focus: Stock Moves 6.3% Higher
by Zacks Equity Research
Aimmune Therapeutics (AIMT) shares rose more than 6% in the last trading session, amid huge volumes.
Alcoa, Cheesecake Factory, Luminex, Ligand Pharmaceuticals and Centene highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Alcoa, Cheesecake Factory, Luminex, Ligand Pharmaceuticals and Centene highlighted as Zacks Bull and Bear of the Day
3 Healthcare Stocks to Buy on Renewed Obamacare Repeal Talks
by Benjamin Rains
Healthcare has been a newsworthy topic for decades, and that is unlikely to cease anytime soon as the Republican effort to repeal and replace the Affordable Care Act, or Obamacare, ramps up ahead of a key Sept. 30 deadline.
Glaxo's Shingles Candidate Gets Positive FDA Committee Vote
by Zacks Equity Research
Glaxo (GSK) declared that an FDA advisory panel has unanimously voted recommending approval for its shingles vaccine candidate, Shingrix, in older patients.
Pfizer Lung Cancer Drug's Overall Survival Data Unfavorable
by Zacks Equity Research
Pfizer (PFE) announced final overall survival data from a phase III study (PROFILE 1014), evaluating its cancer drug Xalkori for first-line treatment of ALK-positive non-small cell lung cancer (NSCLC).
5 Top-Ranked Biotech Stocks to Buy Right Now
by Arpita Dutt
If you are looking to invest in the biotech sector, here is a peek at 5 buy-ranked biotech stocks including Regeneron Pharmaceuticals (REGN).
Lilly to Cut 3,500 Jobs to Invest in New Drugs and Growth
by Zacks Equity Research
Lilly (LLY) plans to reduce its global workforce by approximately 3,500 positions, which should save $500 million. Lilly plans to invest the savings in new drugs and overall growth of the company.
Alnylam Shares Plunge on Patient Death, Dosing Suspended
by Zacks Equity Research
Alnylam (ALNY) announced suspension of dosing in all ongoing studies on its hemophilia candidate, fitusiran, following a patient's death in a phase II study.
Ligand (LGND) Up 9.6% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.